Early Trends for Invasive Pneumococcal Infections in Children After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine

Black, 2000, Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group., Pediatr Infect Dis J, 19, 187, 10.1097/00006454-200003000-00003

Whitney, 2003, Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine., N Engl J Med, 348, 1737, 10.1056/NEJMoa022823

Black, 2007, Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine., Pediatr Infect Dis J, 26, 771, 10.1097/INF.0b013e318124a494

Pilishvili, 2010, Active Bacterial Core SurveillanceEmerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine., J Infect Dis, 201, 32, 10.1086/648593

Pai, 2005, Active Bacterial Core Surveillance Team. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States., J Infect Dis, 192, 1988, 10.1086/498043

Byington, 2006, Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema., Pediatr Infect Dis J, 25, 250, 10.1097/01.inf.0000202137.37642.ab

Steenhoff, 2006, Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia., Clin Infect Dis, 42, 907, 10.1086/500941

Singleton, 2007, Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage., JAMA, 297, 1784, 10.1001/jama.297.16.1784

Pelton, 2007, Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine., Pediatr Infect Dis J, 26, 468, 10.1097/INF.0b013e31803df9ca

Moore, 2008, Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005., J Infect Dis, 197, 1016, 10.1086/528996

Messina, 2007, Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005., Pediatr Infect Dis J, 26, 461, 10.1097/INF.0b013e31805cdbeb

Kaplan, 2010, Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children., Pediatrics, 125, 429, 10.1542/peds.2008-1702

Miller, 2011, Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine., Vaccine, 29, 9127, 10.1016/j.vaccine.2011.09.112

Cohen, 2012, Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media., Pediatr Infect Dis J, 31, 297, 10.1097/INF.0b013e318247ef84

Yeh, 2010, 004 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers., Pediatrics, 126, e493, 10.1542/peds.2009-3027

Green, 2011, Increase in prevalence of Streptococcus pneumoniae serotype 6C at Eight Childrens Hospitals in the United States from 1993 to 2009., J Clin Microbiol, 49, 2097, 10.1128/JCM.02207-10

Cooper, 2011, The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A., Vaccine, 29, 7207, 10.1016/j.vaccine.2011.06.056